MedPath

Tegafur,Gimeracil and Oteracil Potassium

Generic Name
Tegafur,Gimeracil and Oteracil Potassium
Brand Names
-
Drug Type
-
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Indication

用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准;《胆管癌诊断与治疗-外科专家共识》】。

Associated Conditions
-
Associated Therapies
-

RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

Phase 2
Conditions
Rectal Cancer
Interventions
Other: Laboratory test
Other: Medical history and physical examination
Other: BW and height
Other: Performance status
Other: Creatinine clearance
Other: Biomarker
Radiation: Contrasting CT
Other: Adverse event
Other: HBs antigen and HCV antibody
Other: Endoscopy
Other: HBs antibody and HBc antibody
Drug: L-OHP (85 mg/m2)
Drug: S-1
Drug: L-OHP (130mg/m2)
Drug: l-LV
Drug: 5-FU
First Posted Date
2014-10-31
Last Posted Date
2014-10-31
Lead Sponsor
Clinical Research Support Center Kyush
Target Recruit Count
110
Registration Number
NCT02280070
Locations
🇯🇵

Kyushu University Hospital, Fukuoka, Japan

🇯🇵

Kurume University Hospital, Kurume, Japan

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
First Posted Date
2014-08-29
Last Posted Date
2017-07-27
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
73
Registration Number
NCT02229058
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Effects of S-1 and Capecitabine on Coronary Artery Blood Flow

Phase 2
Terminated
Conditions
Rectum Cancer
Esophagus Cancer
Stomach Cancer
Small Bowel Cancer
Colon Cancer
Interventions
First Posted Date
2014-08-13
Last Posted Date
2018-08-28
Lead Sponsor
Heikki Joensuu
Target Recruit Count
20
Registration Number
NCT02216149
Locations
🇫🇮

Helsinki University Central Hospital, Helsinki, Finland

Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

Phase 2
Withdrawn
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2014-05-02
Last Posted Date
2021-02-15
Lead Sponsor
Zhejiang University
Registration Number
NCT02129322
Locations
🇨🇳

First affiliated hospital, Zhejiang University, Hangzhou, China

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer

Phase 2
Conditions
Advanced Pancreatic Cancer
Interventions
First Posted Date
2014-04-28
Last Posted Date
2016-12-22
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
60
Registration Number
NCT02124317
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer

Phase 3
Completed
Conditions
Gastric Cancer
Interventions
Drug: Capecitabine/cisplatin
Drug: Capecitabine
Drug: S-1/cisplatin
Drug: S-1
Drug: Capecitabine/oxaliplatin
Drug: 5-fluorouracil
Drug: 5-fluorouracil/oxaliplatin
First Posted Date
2014-04-15
Last Posted Date
2020-10-23
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
111
Registration Number
NCT02114359
Locations
🇰🇷

Yeongnam University Medical Center, Daegu, Korea, Republic of

🇰🇷

Kyungpook National University Medical Center, Daegu, Korea, Republic of

🇰🇷

Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

and more 11 locations

Study of S-1 Plus LV for Advanced Gastric Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Drug: S-1
Drug: LV
First Posted Date
2014-03-18
Last Posted Date
2014-03-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
39
Registration Number
NCT02090153
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Gaungzhou, Guangdong, China

A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC

Phase 4
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2013-11-28
Last Posted Date
2013-11-28
Lead Sponsor
Zhu Xu
Target Recruit Count
110
Registration Number
NCT01997957
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

First Line Chemotherapy for Advanced Cancer

Phase 2
Terminated
Conditions
Gastric Cancer
Interventions
First Posted Date
2013-11-11
Last Posted Date
2016-06-14
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
36
Registration Number
NCT01980810
Locations
🇨🇳

Department of Medical Oncology,Cancer Hostpital and Institute,CAMS, Beijing, China

Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer

Phase 4
Conditions
Breast Neoplasms
Neoadjuvant Therapy
Interventions
First Posted Date
2013-05-08
Last Posted Date
2013-05-08
Lead Sponsor
Shandong University
Target Recruit Count
240
Registration Number
NCT01849380
Locations
🇨🇳

the Second Hospital of Shandong Universtity, Jinan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath